HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aya Kita Selected Research

sepantronium

9/2018Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155.
1/2015Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
9/2014Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
4/2014Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
9/2013Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
2/2013Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
1/2013Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
10/2012Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
9/2012Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
7/2012Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Aya Kita Research Topics

Disease

18Neoplasms (Cancer)
09/2018 - 09/2007
5Body Weight (Weight, Body)
04/2014 - 09/2007
4Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2018 - 03/2011
3Breast Neoplasms (Breast Cancer)
09/2018 - 03/2011
3Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
04/2014 - 06/2011
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2012 - 03/2011
2Lung Neoplasms (Lung Cancer)
09/2018 - 06/2011
2Triple Negative Breast Neoplasms
01/2013 - 09/2011
2Melanoma (Melanoma, Malignant)
08/2011 - 03/2011
2Prostatic Neoplasms (Prostate Cancer)
03/2011 - 09/2007
1Neoplasm Metastasis (Metastasis)
09/2011
1Lymphoma (Lymphomas)
06/2011
1Sarcoma (Soft Tissue Sarcoma)
03/2011
1Urinary Bladder Neoplasms (Bladder Cancer)
03/2011
1Leukemia
03/2011
1Ovarian Neoplasms (Ovarian Cancer)
03/2011
1Carcinoma (Carcinomatosis)
03/2008

Drug/Important Bio-Agent (IBA)

19sepantroniumIBA
09/2018 - 09/2007
16SurvivinIBA
09/2018 - 09/2007
4Pharmaceutical PreparationsIBA
01/2015 - 03/2008
3Docetaxel (Taxotere)FDA Link
01/2013 - 06/2011
2Rituximab (Mabthera)FDA Link
04/2014 - 10/2012
2Hormones (Hormone)IBA
03/2011 - 09/2007
1Liposomes (Liposome)IBA
09/2014
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
09/2014
1Bendamustine HydrochlorideFDA Link
04/2014
1Cytotoxins (Cytolysins)IBA
01/2013
1ErbB Receptors (EGF Receptor)IBA
01/2012
1Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2012
1Tyrosine Kinase InhibitorsIBA
01/2012
1Protein Kinases (Protein Kinase)IBA
01/2012
1Progesterone Receptors (Progesterone Receptor)IBA
09/2011
1Estrogens (Estrogen)FDA Link
09/2011
1Messenger RNA (mRNA)IBA
08/2011
1Proteins (Proteins, Gene)FDA Link
08/2011
1Small Interfering RNA (siRNA)IBA
08/2011
1taxaneIBA
06/2011
1Histones (Histone)IBA
03/2008
1Histone Deacetylase InhibitorsIBA
03/2008

Therapy/Procedure

7Therapeutics
04/2014 - 10/2010
2Drug Therapy (Chemotherapy)
09/2018 - 10/2012
1Injections
01/2015